Sarcoma  >>  rilotumumab (AMG 102)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
rilotumumab (AMG 102) / Amgen
NCT01105390: AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma

Withdrawn
2
0
US
rilotumumab, AMG 102, anti-HGF monoclonal antibody AMG 102, cisplatin, CACP, CDDP, CPDD, DDP, pemetrexed disodium, ALIMTA, LY231514, MTA, laboratory biomarker analysis
National Cancer Institute (NCI)
Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
05/11
 
NCT01113398: AMG 102 and Avastin for Recurrent Malignant Glioma

Checkmark P2 data-ASCO
Jun 2012 - Jun 2012: P2 data-ASCO
Completed
2
36
US
AMG 102, rilotumumab, Avastin, Bevacizumab
Katy Peters, Amgen
Glioblastoma Multiforme, Gliosarcoma
11/14
09/15
NCT00788957 / 2008-001751-21: Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

Checkmark ASCO-GI 2015
Jan 2015 - Jan 2015: ASCO-GI 2015
Checkmark P1/2 data
Jun 2011 - Jun 2011: P1/2 data
Completed
1b/2
153
US, Canada, RoW
Panitumumab, Vectibix®, Ganitumab, AMG 479, Rilotumumab, AMG 102, Placebo
Amgen
Colon Cancer, Colorectal Cancer, Gastrointestinal Cancer, Metastatic Colorectal Cancer, Rectal Cancer
02/12
10/13

Download Options